Phobia Control Drug May Also Be Useful In Treating Addiction

Main Category: Alcohol / Addiction / Illegal Drugs
Also Included In: Biology / Biochemistry;  Clinical Trials / Drug Trials
Article Date: 07 Nov 2007 - 6:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Scientists at the U.S. Department of Energy's Brookhaven National Laboratory provide further evidence that a drug known as D-cycloserine could play a role in helping to extinguish the craving behaviors associated with drug addiction. Their study found that mice treated with D-cycloserine were less likely to spend time in an environment where they had previously been trained to expect cocaine than mice treated with a placebo.

"Since the association between drugs and the places where they are used can trigger craving and/or relapse in humans, a medication that could aid in the reduction or even extinction of such responses could be a powerful tool in the treatment of addiction," said Carlos Bermeo, a Stony Brook University graduate student working under the direction of Brookhaven Lab neuroscientist Panayotis (Peter) Thanos. Bermeo presented these results in a talk at the Society for Neuroscience annual meeting in San Diego.

D-cycloserine was originally developed as an antibiotic. But it has also been shown to extinguish conditioned fear in pre-clinical (animal) studies, and has been successfully tested in human clinical trials for the treatment of acrophobia (fear of heights). This finding led several researchers to wonder whether D-cycloserine could extinguish drug-seeking behaviors as well.

In 2006, a group of scientists not affiliated with Brookhaven Lab tested this hypothesis in rats. They found that D-cycloserine facilitated the extinction of "cocaine conditioned place preference" -- the tendency for the animals to spend more time in a chamber where they had been trained to expect cocaine than in a chamber where they had no access to the drug.

The Brookhaven study builds on the previous work and adds information on the drug dose effect, the lasting properties of the treatment, and the locomotor effects of this compound.

Bermeo and Thanos' group worked with C57bL/c mice. Animals were first trained to receive cocaine in a particular environment. Once conditioned place preference was established (that is, animals willingly spent more time in a cocaine-paired environment than in a "neutral" environment), the mice were treated with either D-cycloserine or saline and allowed to spend forty minutes in either the previously cocaine-paired environment (with the drug no longer available) or the neutral environment.

"This paradigm would be analogous to a clinical approach where the addict is returned to the environment that previously was the place of drug use (e.g., the neighborhood or home), but this time with no drug available," said Thanos. "Reduced seeking of the drug in the same environment -- that is extinction behavior -- is a great indicator of future success in treatment and reduced chance of relapse," he added.

Mice treated with D-cycloserine showed less preference for the cocaine-paired environment and did this more rapidly than mice treated with saline. The low dose (15 milligrams D-cycloserine per kilogram of body weight, given intraperitonially) showed a 10 percent decrease in time spent in the previously cocaine-paired environment, and the high dose (30 mg/kg i.p.) showed a 17 percent decrease in the time spent in the previously cocaine-paired environment. The high dose produced a more pronounced and consistent extinction than the lower dose.

Interestingly, animals treated with the high dose of D-cycloserine exhibited lower locomotor activity compared to both the low-dose D-cycloserine group and the saline-treated animals. These two groups exhibited similar levels of locomotor activity. This indicates that dosing may have to be fine tuned to achieve optimal efficacy with minimum side effects.

"It's important to remember that these are very preliminary results from a small animal study," Thanos cautions. "Much further research will be required before testing this drug in humans. But it is inspiring to know that this drug may show promise in treating cocaine addiction, which continues to take a toll on society and for which no pharmacological treatment currently exists."

----------------------------
Article adapted by Medical News Today from original press release.
----------------------------

This work was supported by the Intramural Research Program of National Institute on Alcohol Abuse and Alcoholism at the National Institute of Health (NIH), and by the Office of Biological and Environmental Research within the U.S. Department of Energy's Office of Science.

Brookhaven Lab has a world-renowned research program aimed at understanding the neurological mechanisms and consequences of drug addiction. This program is fueled in part by the Department of Energy's long-standing support of brain-imaging technologies developed as a direct outgrowth of their commitment to basic physics and chemistry research.

One of ten national laboratories overseen and primarily funded by the Office of Science of the U.S. Department of Energy (DOE), Brookhaven National Laboratory conducts research in the physical, biomedical, and environmental sciences, as well as in energy technologies and national security. Brookhaven Lab also builds and operates major scientific facilities available to university, industry and government researchers. Brookhaven is operated and managed for DOE's Office of Science by Brookhaven Science Associates, a limited-liability company founded by the Research Foundation of State University of New York on behalf of Stony Brook University, the largest academic user of Laboratory facilities, and Battelle, a nonprofit, applied science and technology organization.

Source: Karen McNulty Walsh
DOE/Brookhaven National Laboratory